inflammatory diseases

News
Novartis' Cosentyx heads for fourth indication

Novartis' Cosentyx heads for fourth indication

Novartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it improved symptoms in patients with non-radiographic axial spondyloar